P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial
D. Ross Camidge(University of Colorado Denver), D. Kim(Seoul National University Hospital), Natasha B. Leighl(Princess Margaret Cancer Centre), William M. Reichmann(Ariadne Diagnostics (United States)), Egbert F. Smit(Dutch Cancer Society), E. Kim(Harvard University), Myung‐Ju Ahn(Sungkyunkwan University), Howard West(Vyne Therapeutics (United States)), David Kerstein(Ariadne Diagnostics (United States)), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Karin Holmskov Hansen(Odense University Hospital), Harry J.M. Groen(University Medical Center Groningen), Scott Gettinger(Yale Cancer Center), Marcello Tiseo(University of Parma), Corey J. Langer(University of Pennsylvania), Rudolf M. Huber(Clinica de Pneumologie Iaşi), S. Kim(Ulsan College), Maximilian J. Hochmair(Karl Landsteiner Society)
Cited by 3
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k